Boehringer Ingelheim announces appointment to Board of Managing Directors

4 weeks ago

Harsha Deshmukh Harsha Deshmukh Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for…

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

4 weeks ago

New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for…

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

4 weeks ago

Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ETNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG…

Kane Biotech Announces Third Quarter 2025 Financial Results

4 weeks ago

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced…

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

4 weeks ago

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,…

Shriners Hospitals for Children Canada and Children’s Hospital at LHSC launch landmark research program to advance care in rare childhood bone disorders

4 weeks ago

One-year anniversary of affiliation marked by national expansion in research and care for kids with complex conditionsMONTREAL and LONDON, Ontario,…

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

4 weeks ago

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),…

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

4 weeks ago

Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK)…

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

4 weeks ago

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

4 weeks ago

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…